Close Menu

NEW YORK – Alzheimer's disease testing firm ADx Healthcare said today that it has partnered with Osaka, Japan-based Nakanoshima Clinic and Ixlayer, a San Francisco health IT company, to launch a polygenic-risk score for early detection of Alzheimer’s disease in Japan.

The test, called GenoRisk, assays 32 genetic loci, with results analyzed and interpreted by ADx Healthcare's medical team. According to the firm's CEO Steve Booth, the panel included both risk-associated and protective genes that influence Alzheimer's disease risk.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.